4-fluoro-N-(4-sulfamoylbenzyl) benzene sulfonamide attenuate nicotine induced Behavioral sensitization

Background and Aim : Frequent exposure to nicotine produce a persistent increase in locomotors effects of mice a phenomenon called sensitization. Due to nicotine sensitization relapse is the most common outcome. Aim of the study The aim of this study is to examine the effect of 4-fluoro-N-(4-sulfamoylbenzyl) benzene sulfonamide in nicotine induced behavioral sensitization. We investigate the effect of 4-fluoro-N-(4-sulfamoylbenzyl) benzene sulfonamide on acquisition and expression of nicotine induced behavioral sensitization in mice.Methods : Selected groups of mice were administered nicotine 0.5mg/kg, while one group receives saline for seven consecutive days. After 3 days of drug free period two groups received saline and nicotine respectively, while test groups receive 4-fluoro-N-(4-sulfamoylbenzyl) benzene sulfonamide at a dose of 20,40,60 mg/kg. One hour after drug administration challenged dose of nicotine was administered and locomotor activity was observed on day 1,3,5,7 and 11. In another’s set of experiment selected group of mice were administered concomitant 4-fluoro-N-(4-sulfamoylbenzyl) benzene sulfonamide at a dose of 20, 40, 60mg/kg daily before nicotine 0.5mg/kg using the same protocol for the same period of time to the entire groups. After 3 days of abstinence period challenge dose of nicotine was administered and locomotion activity was observed after at, 3, 5, 7 and 11 days.Results : Results showes that F2 compound in all 3 doses significantly attenuated acquisition and expression of nicotine behavioral sensitization in miceConclusion : In our study we found that 4-fluoro-N-(4-sulfamoylbenzyl) benzene sulfonamide was able to antagonize the acquisition and expression of nicotine induces behavioral sensitization in Balb/c mice.Further studies are warranted to explore the exact mechanism in the reward pathway in the specific brain areas.

Keywords:

F2 compound , Sulfonamides , nicotine sensitization , Pharmacotherapy , drug addiction , locomotor activity